Search Orphan Drug Designations and Approvals
-
Generic Name: | ansuvimab |
---|---|
Date Designated: | 03/30/2020 |
Orphan Designation: | Post-exposure prophylaxis against Ebola virus infection |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Ridgeback Biotherapeutics LP 3162 Commodore Plaza Suite 3E Miami, Florida 33133- United States The sponsor address listed is the last reported by the sponsor to OOPD. |
-